Let's focus on what we can do!

By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Brittle Bone Disease
  • >
  • Adge Pharmaceuticals secures license to evaluate two new programs in rare pediatric diseases – Digital Journal

Adge Pharmaceuticals secures license to evaluate two new programs in rare pediatric diseases – Digital Journal

Saturday, 26 March, 2022

Adge Pharmaceuticals secures license to evaluate two new programs in rare pediatric diseases – Digital Journal

Image: Adge Pharmaceuticals

 
Adge Pharmaceuticals Inc. has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. Adge is now evaluating the molecule for the treatment of Rett syndrome and Osteogenesis imperfecta and potentially other indications with unmet medical needs.
Adge has complemented the already existing data package with relevant preclinical data for Rett Syndrome and Osteogenesis imperfecta and is in communications with the US FDA to move this asset expeditiously to the clinic.
Read more at: https://www.digitaljournal.com/pr/adge-pharmaceuticals-secures-license-to-evaluate-two-new-programs-in-rare-pediatric-diseases

Categories :
  • Brittle Bone Disease
  • Latest Headlines
Socials :

Recent posts